Close menu




April 4th, 2023 | 17:04 CEST

Race against cancer: BioNTech, Bayer, Defence Therapeutics

  • Biotechnology
  • Cancer
Photo credits: pixabay.com

BioNTech first became known to the general public about three years ago. At that time, the pandemic was rampant and the first vaccine plans were making the rounds in the media. Among all the big names, BioNTech was initially one of many options for the public. In the meantime, the Company has become so dominant in Germany that the competition has been left behind. We look at what this means for investors and the pharmaceutical industry.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , BAYER AG NA O.N. | DE000BAY0017 , DEFENCE THERAPEUTICS INC | CA24463V1013

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    BioNTech: Dominating the German biotech sector

    A few years ago, BioNTech could be mentioned in the same breath as Qiagen, CureVac or Morphosys. Today, the Mainz-based company towers above them all. The success of the Corona vaccine has given the Company a dominant market position. Researchers from the Rhine have around EUR 13.8 billion in cash on hand, not including outstanding receivables from partner Pfizer of around EUR 7 billion - and can therefore invest in the future like hardly any other company. But that is not all. While many biotechs have to raise capital through equity financing, BioNTech still has billions of euros in vaccines. According to Handelsblatt, BioNTech currently has a turnover of around EUR 36 billion, which is two and a half times as much as the entire German biotech sector. When looking to the future, these starting conditions are outstanding: BioNTech can invest in research at a time when many biotechs are having to tighten their belts due to poor financing conditions - and should further expand its supremacy.

    Established pharmaceutical companies like Bayer are also likely to look south along the Rhine with envy. While Bayer seems torn between its seed division and a stronger commitment to the health sector, at BioNTech, everything revolves around the fight against cancer. Nevertheless, there are also positive developments at Bayer: In the past quarters, Bayer stepped on the cost brakes, expanded its sustainability strategy and moved a stroke drug into a clinical phase III study. Add to that a dividend yield of more than 4% - this is pleasing for conservative investors, but the payout also shows that Bayer's organic growth potential seems limited.

    Bayer: Business seems saturated

    The pure comparison between Bayer and BioNTech favours the Mainz-based company. But Bayer is also solidly positioned - only the perspective for growth could be better in the comparatively saturated business with seeds and health products. The situation is different at BioNTech: its portfolio includes several blockbusters in the field of cancer alone - no wonder the Company is already valued at almost EUR 30 billion. An alternative to BioNTech with a much lower market capitalisation in the low three-digit million range could be the share of Defence Therapeutics. With Accum™, the Canadians have a versatile technology for transporting active agents into diseased cells in their portfolio. Several Phase I trials are expected to be launched in the coming quarters alone.

    Defence Therapeutics: Accum™ as a sought-after multi-tool

    The projects of Defence Therapeutics involve therapeutic vaccines against various types of cancer, the use of Accum™ in a potentised variant under the AccuTOX™ brand as a chemotherapeutic agent, and a protein-based vaccine against the HP virus, which can trigger cervical cancer. Defence Therapeutics has advanced all projects in parallel in the past months and gained prominent support in various areas. For example, the renowned City of Hope hospital in the Los Angeles area is accompanying the application process for clinical trials of AccuTOX™, and the well-known Canadian biotech incubator CQDM, which is associated with large pharmaceutical companies, is jointly financing a new cancer vaccine platform with Defence.

    At a time when biotech companies, such as BioNTech, are increasingly outpacing the competition, the principle for classic pharmaceutical companies is "stick with it". Companies such as AstraZeneca have already made acquisitions in recent months and taken over innovative biotech companies. As with Defence Therapeutics, the focus was primarily on innovative processes such as mRNA or drug delivery. Since Defence Therapeutics' technology is considered highly flexible, the Canadians could also come into the focus of large corporations. Defence has already convinced the French state-owned group Orano and announced a cooperation in the field of nuclear medicine a few weeks ago - here, too, Accum™ is expected to showcase its capabilities.


    Investors are currently spoilt for choice. The only thing that seems certain is that biotech companies have growth on their side thanks to innovative technology compared to classic pharmaceutical companies. While the valuations of BioNTech already seem ambitious, the share price of Defence Therapeutics still contains a fair amount of scepticism. For speculative investors, however, it is worth taking a closer look at the up-and-coming growth stock, which was only recently included in the CSE 25 Index.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Fabian Lorenz on July 23rd, 2024 | 06:50 CEST

    70% with Evotec shares? Caution with BASF? Almonty Industries tempts investors to get in!

    • Mining
    • Tungsten
    • hightech
    • chemicals
    • Biotechnology

    Will BASF miss market expectations in the second half of the year? Analysts believe so. The chemical giant's revenues are already expected to fall in the second quarter. So, should one sell the shares now? The Evotec share was bought yesterday. Analysts believe that the profit warning from Sartorius should not be overestimated and see over 70% upside potential. However, patience is required. The Almonty Industries share also appears too favourable. The commissioning of a huge tungsten mine is imminent, and not only companies such as Taiwan Semiconductor and Rheinmetall need the critical metal for their high-tech products. So, when will the share break out?

    Read

    Commented by Stefan Feulner on July 17th, 2024 | 06:30 CEST

    BioNTech, Cardiol Therapeutics, Bayer - Prepared for the next wave

    • Biotechnology
    • Biotech
    • Pharma

    The assassination attempt on former and possibly future US President Donald Trump was clearly the dominant topic at the weekend, causing both gold and the largest cryptocurrencies to surge at the start of the week. Still largely unnoticed, however, the COVID-19 figures are rising again, especially in the United States, which could halt the downward spiral for vaccine manufacturers such as BioNTech/Pfizer and Moderna.

    Read

    Commented by Fabian Lorenz on July 11th, 2024 | 06:55 CEST

    Shares with breakthrough potential? Evotec, Varta, and Carbon Done Right Developments

    • Sustainability
    • Pharma
    • Biotechnology
    • renewableenergies
    • CarbonCredits

    Evotec is currently going from strength to strength. Yesterday, a partnership with pharmaceutical giant Pfizer boosted the share price. Will the resistance at EUR 10 now finally fall? There has also been positive news for Varta recently. Is the possible collaboration with Porsche a game changer? Analysts have a clear opinion on this matter. At Carbon Done Right Developments, investors are eagerly awaiting the AIM listing. Once it happens, the share price could explode, as the Company is working on an ecosystem within a billion-dollar market. Should you position yourself now? In any case, all three companies are working towards a breakthrough.

    Read